TOKYO, Jan 12 (Reuters) - Japan's benchmark Nikkei share average inched up to close at a fresh three-decade high on Tuesday, as drug makers led the charge on a report that Chugai Pharmaceutical's drug was effective in treating COVID-19 patients.
The Nikkei index ended 0.09% higher at 28,164.34 after recovering from early declines, while the broader Topix index .TOPX edged up 0.16% to 1,857.94.
"Investors bought back stocks as soon as the market started falling, showing the fundamental strength of demand," said Masahiro Ichikawa, chief market strategist at Sumitomo Mitsui DS Asset Management.
"They (also) got confidence in the market as U.S. futures rose overnight." MKTS/GLOB .N
The COVID-19 treatment news comes at a time when Japan plans to expand its declaration of state of emergency to three western prefectures including Osaka to stem the spread of COVID-19, according to local media. other shares, SoftBank Group gained 1.36% after a fund it manages sold part of its stake in Uber Technologies UBER.N for $2 billion.
Retail stocks rose, led by a 5.52% rise in Ryohin Keikaku 7453.T after the Muji retail stores operator posted a 69% jump in quarterly net profit. Lawson 2651.T rose 2.24%, while Watts Co 2735.T jumped 10.37%.
Bucking the trend, automakers slid after Toyota Motor 7203.T and Honda Motor 7267.T said they would cut vehicle production this month due to a shortage of semiconductors. fell 0.59% and Honda Motor declined 1.55%.
Add Chart to Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
- Enrich the conversation
- Stay focused and on track. Only post material that’s relevant to the topic being discussed.
- Be respectful. Even negative opinions can be framed positively and diplomatically.
- Use standard writing style. Include punctuation and upper and lower cases.
- NOTE: Spam and/or promotional messages and links within a comment will be removed
- Avoid profanity, slander or personal attacks directed at an author or another user.
- Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
- Only English comments will be allowed.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.